GSK plc
General ticker "GLAXF" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $77.1B (TTM average)
GSK plc follows the US Stock Market performance with the rate: 26.9%.
Estimated limits based on current volatility of 1.3%: low 23.73$, high 24.34$
Factors to consider:
- Company pays dividends (semi-annually): last record date 2025-11-14, amount 0.21$ (Y1.72%)
- Total employees count: 90422 as of 2022
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [15.50$, 23.35$]
- 2025-12-31 to 2026-12-31 estimated range: [16.10$, 24.18$]
Financial Metrics affecting the GLAXF estimates:
- Positive: with PPE of 0.1 at the end of fiscal year the price was very low
- Positive: 7.86 < Operating profit margin, % of 12.82
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 4.73
- Positive: -4.48 < Investing cash flow per share per price, % of -2.28
- Positive: Industry inventory ratio change (median), % of -0.66 <= -0.15
- Negative: 0.79 < Interest expense per share per price, % of 1.18
- Positive: 5.52 < Industry operating cash flow per share per price (median), % of 8.11
- Positive: 18.93 < Shareholder equity ratio, % of 22.99 <= 41.86
Short-term GLAXF quotes
Long-term GLAXF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | £29,324.00MM | £30,328.00MM | £31,376.00MM |
| Operating Expenses | £22,891.00MM | £23,583.00MM | £27,355.00MM |
| Operating Income | £6,433.00MM | £6,745.00MM | £4,021.00MM |
| Non-Operating Income | £-805.00MM | £-681.00MM | £-544.00MM |
| Interest Expense | £879.00MM | £775.00MM | £640.00MM |
| R&D Expense | £5,488.00MM | £6,223.00MM | £6,401.00MM |
| Income(Loss) | £5,628.00MM | £6,064.00MM | £3,477.00MM |
| Taxes | £707.00MM | £756.00MM | £526.00MM |
| Profit(Loss)* | £14,956.00MM | £4,928.00MM | £2,575.00MM |
| Stockholders Equity | £10,598.00MM | £13,347.00MM | £13,671.00MM |
| Inventory | £5,146.00MM | £5,498.00MM | £5,669.00MM |
| Assets | £60,146.00MM | £59,005.00MM | £59,463.00MM |
| Operating Cash Flow | £7,403.00MM | £6,768.00MM | £6,554.00MM |
| Capital expenditure | £2,258.00MM | £2,344.00MM | £2,982.00MM |
| Investing Cash Flow | £-8,772.00MM | £-1,595.00MM | £-1,229.00MM |
| Financing Cash Flow | £823.00MM | £-5,641.00MM | £-4,726.00MM |
| Earnings Per Share** | £3.71 | £1.20 | £0.63 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.